EYEN Stock Forecast 2025-2026
Distance to EYEN Price Targets
EYEN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Eyenovia (EYEN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on EYEN and similar high-potential opportunities.
Latest EYEN Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, EYEN has a neutral consensus with a median price target of $2.00 (ranging from $2.00 to $2.00). Currently trading at $1.13, the median forecast implies a 77.0% upside. This outlook is supported by 0 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Caufield at HC Wainwright & Co., projecting a 77.0% upside. Conversely, the most conservative target is provided by Matthew Caufield at HC Wainwright & Co., suggesting a 77.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EYEN Analyst Ratings
EYEN Price Target Range
Latest EYEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EYEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Feb 6, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Nov 18, 2024 | Ladenburg Thalmann | Matthew Kaplan | Neutral | Downgrade | $0.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Matthew Caufield | Neutral | Downgrade | $2.00 |
| Nov 15, 2024 | William Blair | Tim Lugo | Market Perform | Downgrade | $0.00 |
| Nov 15, 2024 | Brookline Capital | Kemp Dolliver | Hold | Downgrade | $0.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Jul 24, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| May 16, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Mar 19, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Nov 1, 2023 | William Blair | Tim Lugo | Outperform | Initiates | $0.00 |
| Oct 17, 2023 | Brookline Capital | Kemp Dolliver | Buy | Initiates | $8.00 |
| Aug 18, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| May 12, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Apr 19, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Apr 3, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
Eyenovia Inc. (EYEN) Competitors
The following stocks are similar to Eyenovia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Eyenovia Inc. (EYEN) Financial Data
Eyenovia Inc. has a market capitalization of $3.09M with a P/E ratio of 0.0x. The company generates $57,336 in trailing twelve-month revenue with a -6,749.5% profit margin.
Revenue growth is +985.1% quarter-over-quarter, while maintaining an operating margin of -29,342.7% and return on equity of +380.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Eyenovia Inc. (EYEN) Business Model
About Eyenovia Inc.
Develops advanced therapies for eye conditions.
Eyenovia Inc. generates revenue by developing and commercializing microdose treatments for various eye-related conditions. The company leverages its innovative microdosing technology to enhance the efficacy and safety of ocular drug delivery, targeting chronic eye diseases such as presbyopia and myopia.
Headquartered in New York, Eyenovia Inc. is positioned as a pioneer in the ophthalmic therapy market. The company focuses on strategic collaborations and ongoing research to advance its technology and improve treatment options for patients, thereby playing a crucial role in the evolution of eye care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
57
CEO
Mr. Michael M. Rowe
Country
United States
IPO Year
2018
Website
www.eyenovia.comEyenovia Inc. (EYEN) Latest News & Analysis
Latest News
The company plans to submit for regulatory approval of the Optejet UFD in Q4 2025.
Regulatory approval timelines can significantly impact a company's valuation and stock performance, as successful launches may lead to increased revenue and market share.
Betaliq and Eyenovia plan to merge, creating a publicly-listed eye care company that will integrate Betaliq's glaucoma drug delivery technology with Eyenovia's device platform.
The merger could enhance market competitiveness and innovation in eye care, potentially increasing revenue streams and shareholder value for the new company.
Eyenovia, Inc. (NASDAQ: EYEN) has regained compliance with Nasdaq listing requirements, including minimum bid price and low-priced stocks rules, as of February 26, 2025.
Eyenovia's compliance with Nasdaq listing requirements boosts investor confidence, indicating financial stability and potential for growth, which can positively impact stock performance.
The Company has amended its terms to defer all interest and principal payments until September 2025, enhancing financial flexibility and reducing short-term cash requirements.
The amendment enhances the company's liquidity by deferring payments, potentially improving its financial stability and ability to invest, which can positively impact stock performance.
Eyenovia aims to submit for U.S. device regulatory approval in Q4 2023, a significant move towards commercialization.
Eyenovia's upcoming regulatory submission signals potential market entry and revenue generation, impacting stock value and investor sentiment.
Eyenovia Announces 1-for-80 Reverse Stock Split
2 months agoEyenovia plans a reverse stock split to meet Nasdaq's minimum bid price requirement while exploring strategic alternatives.
A reverse stock split may boost Eyenovia's share price to meet Nasdaq standards, impacting liquidity and market perception during its strategic review.
Frequently Asked Questions About EYEN Stock
What is Eyenovia Inc.'s (EYEN) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Eyenovia Inc. (EYEN) has a median price target of $2.00. The highest price target is $2.00 and the lowest is $2.00.
Is EYEN stock a good investment in 2025?
According to current analyst ratings, EYEN has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EYEN stock?
Wall Street analysts predict EYEN stock could reach $2.00 in the next 12 months. This represents a 77.0% increase from the current price of $1.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Eyenovia Inc.'s business model?
Eyenovia Inc. generates revenue by developing and commercializing microdose treatments for various eye-related conditions. The company leverages its innovative microdosing technology to enhance the efficacy and safety of ocular drug delivery, targeting chronic eye diseases such as presbyopia and myopia.
What is the highest forecasted price for EYEN Eyenovia Inc.?
The highest price target for EYEN is $2.00 from Matthew Caufield at HC Wainwright & Co., which represents a 77.0% increase from the current price of $1.13.
What is the lowest forecasted price for EYEN Eyenovia Inc.?
The lowest price target for EYEN is $2.00 from Matthew Caufield at HC Wainwright & Co., which represents a 77.0% increase from the current price of $1.13.
What is the overall EYEN consensus from analysts for Eyenovia Inc.?
The overall analyst consensus for EYEN is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are EYEN stock price projections?
Stock price projections, including those for Eyenovia Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.